• Explore /
  • Poster
  • / CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Abstract Poster

Authors

null

Jin Li

East Hospital Affiliated to Tongji University, Shanghai, China

Jin Li , Yuxian Bai , Qingshan Li , YouEn Lin , Hao Jiang , Zhendong Chen , Rong Huang , Na Li , Yanxia JI , Shujun Yang , Wensheng Qiu , Bo Liu , Jufeng Wang , Kangsheng Gu , Jie Fu , Bo Wang , Jin Hu , Yan Xu , Qingmei Shi , Jianxin Yang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04187352

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS255)

DOI

10.1200/JCO.2021.39.3_suppl.TPS255

Abstract #

TPS255

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jaffer A. Ajani

First Author: Hendrik-Tobias Arkenau

First Author: Luhua Wang

First Author: Jianming Xu